ClinicalTrials.gg
CompletedNCT06833658Updated Sep 28, 2026

Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer

An interventional study of Experimental: Aromatherapy with essential oil intervention and Control Group 0.9% Isotonic Saline in Pancreatic Carcinoma, sponsored by Peking University First Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2024, registered Dec 2024).
Updated Sep 28, 2026Now CompletedFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 635 studies in Pancreatic Neoplasms with a site in China — 338 open to participants now, 363 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Enrollment
118th of 513
156 · median 57
Started
2024
with 107 others
No phase
103 of 635
44 open now
Registered
463rd of 635
by date

Among the 635 studies in Pancreatic Neoplasms with a site in China, this one is the 118th largest by enrollment of the 513 interventional ones that give a count, is one of 108 that started in 2024, is one of 103 with no phase, and was the 463rd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

338 of the 635 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

333 more — sign in →

All 338 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 635 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to investigate whether aromatherapy essential oils are effective in alleviating anxiety and depression in participants undergoing perioperative pancreatic cancer treatment. Researchers compared aromatherapy essential oils with a placebo (a substance that appears similar but contains no essential oils) to determine their efficacy in reducing anxiety and depression in these participants. Participants were required to undergo aromatherapy for 2 hours daily over a period of 15 days. Assessments of anxiety and depression were conducted one day before surgery, 14 days after surgery, and 42 days after surgery, with their scores recorded accordingly.

Read the detailed description

Female participants in this study must not be pregnant or breastfeeding during the project period. Although the essential oils used in aromatherapy have minimal effects on infants, there remains a slight risk of developmental issues. Therefore, participants are required to use contraception. If pregnancy occurs or is suspected during the study period, the participant must immediately notify the researcher to terminate their participation and receive further guidance. Male participants are also required to use contraception.Participation in this study is entirely voluntary and free of charge. You may choose not to participate or withdraw at any time, and this will not have any adverse effects on your medical care. If you decide to withdraw, please promptly inform your study physician to obtain relevant health advice. We will also promptly inform you of any significant information that may affect your decision to participate.Regulatory authorities may decide to terminate the study during the research period. If the study is concluded prematurely, we will notify you immediately, and your study physician will provide recommendations for subsequent treatment based on your health condition. If you choose to withdraw from the study midway, we will offer a final follow-up, but you have the option not to participate. After withdrawing from the study, if there is new information concerning your health and rights, we may contact you. Following your withdrawal, your information will be kept strictly confidential until its destruction and will not be further used or disclosed. However, in certain exceptional circumstances, even after your withdrawal or the conclusion of the study, researchers may still use or disclose your information.Unless it affects the scientific integrity of the research or the evaluation of data security, your information will not be disclosed; only information necessary for research, teaching, and other related activities will be provided, excluding personal identification details such as names and ID numbers. If required by government regulatory authorities, all research information, including your participation details, will be provided.If participation in this study results in any health impairment, please contact the researchers (Liu Xiaoyi, 83572652) immediately. We will promptly provide necessary medical treatment and offer compensation in accordance with national legal regulations.Your personal information and participation in this study will be strictly confidential and will not be disclosed to anyone outside the research team without authorization. All researchers are obligated to protect your privacy. Your data will be stored in a locked file cabinet and will only be accessible to authorized researchers. To ensure compliance with research regulations, government or ethics committee members may need to review your information. When the research results are published, your personal data will not be disclosed.If you have any questions regarding the rights and interests of the participants, you may contact the Biomedical Research Ethics Committee of Peking University First Hospital at the following telephone number: 010-66119025.

Informed Consent Signature Page Subject's Informed Consent Statement The researcher has explained to me the background, purpose, procedures, risks, and benefits of the study titled "The Effect of Aromatherapy Essential Oils on Anxiety and Depression in Perioperative Pancreatic Cancer Participants." I have had sufficient time and opportunity to ask questions, and I am satisfied with the answers provided by the researcher. I know whom to contact if I have further questions or need additional information. I have read this informed consent form and decided to participate in this study. I understand that I may withdraw from this study at any time during the research period without providing any reason. I have been informed that I will receive a copy of this informed consent form, which includes both my signature and the researcher's signature.

Subject's Signature: ___________________________ Date: _______________

Researcher's Declaration I have explained to the subject the background, purpose, procedures, risks, and benefits of the study titled "The Effect of Aromatherapy Essential Oils on Anxiety and Depression in Perioperative Pancreatic Cancer Participants." I have provided sufficient time for the subject to read the informed consent form, discuss it with others, and have answered all questions regarding the study. I have informed the subject of the contact information for any research-related inquiries. I have also informed the subject that they may withdraw from the study at any time without providing any reason.

Researcher's Signature: ___________________________ Date: _______________

03

Conditions studied

  • Pancreatic Carcinoma

Keywords

  • Aromatherapy with essential oil intervention
  • pancreatic carcinoma
  • Anxiety
  • Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet diagnostic criteria in Chinese Anti-Cancer Association Guidelines for pancreatic cancer
  • Age ≥18 years
  • required, non-lactation period
  • Consistent with surgical indications
  • Surgical procedures: pancreaticoduodenectomy, extended pancreaticoduodenectomy, costocaudectomy, total pancreatectomy, subtotal pancreatectomy, pyloric-sparing pancreaticoduodenectomy
  • Elective surgery without preoperative radiotherapy or chemotherapy
  • Normal communication
  • Preoperative SAS score ≥50 or SDS score ≥53
  • from subject or guardian

Exclusion criteria

Exclusion Criteria:

  • History of mental illness or cognitive impairment
  • Severe liver/kidney disease, cardiopulmonary dysfunction, tumor recurrence/
  • Allergy or intolerance to aromatic reagents, olfactory disorders, acute respiratory disease, serious complications (unstable vital signs, blood clotting disorders, irreversible metabolic diseases)
  • Poor compliance with study protocol or participation in similar studies
  • Termination due to disease treatment or condition changes
  • Withdrawal for personal reasons
  • Deemed unsuitable by investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Aromatherapy with essential oil intervention

    The 15-day intervention commenced one day prior to surgery and concluded on the 13th post-operative day. Psychological support was delivered through bedside face-to-face interviews with patients. Aromatherapy, customized to meet the psychological needs of pancreatic cancer patients, was employed as part of the intervention. A senior aromatherapist developed the protocol, selecting pleasant essential oils diluted at a ratio of 1-2 drops in 70ml of water. The aromatherapy was administered twice daily for one hour each session using an aromatherapy diffuser.During aromatherapy, nurses should inspect patients every 30 minutes to ensure comfort, and take immediate action if discomfort is reported. Prior to surgery, patients complete anxiety and depression self-assessment scales on the 14th and 42nd days post-operation. If discharged early, a telephone follow-up with a nurse on the 42nd day is conducted to complete the assessment.

    Other: Experimental: Aromatherapy with essential oil intervention

  • Placebo comparator
    control group

    The control group offers high - quality and personalized nursing care to patients in line with the "High - quality Nursing Service" principles. The care details are as follows: 1. Pre - operation: Present pancreatic cancer knowledge, such as causes, common symptoms, treatment methods, and the need for surgery. Answer patients' queries promptly to reduce their fear of the disease and surgery. 2. Post - operation: Report the surgical outcome, explain common post - op complications and solutions to relieve negative emotions. 3. Post - operation: Intensify post - op education on drainage tube care, activity guidelines, disease knowledge, and diet advice. Strengthen mental health education, encourage family members to show more concern for patients, and enhance family support. 4. Pre - discharge: Provide discharge instructions to patients and their families. Guide patients who need tube removal and suture removal after discharge to make online appointments for outpatient follow - up.

    Other: Control Group 0.9% Isotonic Saline

Interventions

  • OtherExperimental: Aromatherapy with essential oil intervention

    Aromatherapy, customized to meet the psychological needs of pancreatic cancer patients, was employed as part of the intervention. A senior aromatherapist developed the protocol, selecting pleasant essential oils diluted at a ratio of 1-2 drops in 70ml of water. The aromatherapy was administered twice daily for one hour each session using an aromatherapy diffuser.During aromatherapy, nurses should inspect patients every 30 minutes to ensure comfort, and take immediate action if discomfort is reported.

    Also known as: Essential oil aromatherapy

  • OtherControl Group 0.9% Isotonic Saline

    1\. Pre - operation: Present pancreatic cancer knowledge, such as causes, common symptoms, treatment methods, and the need for surgery. Answer patients' queries promptly to reduce their fear of the disease and surgery. 2. Post - operation: Report the surgical outcome, explain common post - op complications and solutions to relieve negative emotions. 3. Post - operation: Intensify post - op education on drainage tube care, activity guidelines, disease knowledge, and diet advice. Strengthen mental health education, encourage family members to show more concern for patients, and enhance family support. 4. Pre - discharge: Provide discharge instructions to patients and their families. Guide patients who need tube removal and suture removal after discharge to make online appointments for outpatient follow - up.

06

What researchers measure

Primary outcomes

  1. Self-rating Anxiety Scale (SAS)

    Zung\[20\] self-rating Anxiety Scale was adopted, which was compiled in 1971, with a total of 20 items, and scored according to the four levels of "no or occasionally (1 point)","sometimes (2 points)", "often (3 points)" and"always (4 points) ", in which items 5, 9, 13, 17 and 19 were scored in reverse. Add the scores of all items, multiply by the coefficient 1.25, and take their integer parts and remember them to the standard score. After the Chinese revision of the scale in China, the norm results are judged as follows: SAS standard score \<50 is no anxiety, 50 \~ 59 is mild anxiety, 60 \~69 is moderate anxiety, ≥70 is severe anxiety, the higher the score, the more serious the anxiety. Cronbach's a coefficient of the scale was 0.799, indicating good reliability and validity.

    Time frame: Within 24 hours on the day of admission, after intervention (14 days after surgery) and 28 days after intervention (42 days after surgery).

  2. Self-rating Depression Scale (SDS)

    The Zung\[21\] Self-rating Depression Scale, which was developed in 1965, was used to assess the subjective feelings of individuals with depressive symptoms. There are 20 items that are scored on a 4-point scale based on the frequency of symptoms, where "1" means no or occasionally, "2" means sometimes, "3" means often, and "4" means always. Items 2, 5, 6, 11, 12, 14, 16, 17, 18, and20 are negative scoring questions, which are calculated as 4 to 1 points. Add the scores of all items, multiply by the coefficient1.25, and take their integer parts and remember them to the standard score. A standard score of \<53 indicates no depression, a score of 53-62 indicates mild depression, a score of 63-72 indicates moderate depression, a score of ≥73 indicates severe depression, and the higher the score, the more severe the depression. Cronbach's a coefficient of this scale was 0.78, indicating good reliability and validity.

    Time frame: Within 24 hours on the day of admission, after intervention (14 days after surgery) and 28 days after intervention (42 days after surgery).

07

Study locations

1 site
  • Peking University First Hospital consecutively
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Aug 2025, 11 months.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's 11 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: start Nov 2025 → Sep 2024, primary completion Dec 2025 → Aug 2025 and completion Dec 2025 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Feb 19, 2025
StartActual
Sep 1, 2024was Nov 2025
Primary completionActual
Aug 3, 2025was Dec 2025
CompletionActual
Oct 3, 2025was Dec 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Sep 28, 2026
Sites
1 site added — first site in China
Show site
  • Peking University First Hospital consecutively · Beijing, China
Sep 28, 2026
Start date
Nov 1, 2025→Sep 1, 2024 (actual)
Sep 28, 2026
Primary completion
Dec 3, 2025→Aug 3, 2025 (actual)
Sep 28, 2026
Study completion
Dec 3, 2025→Oct 3, 2025 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Completed
    1 site added — first site in China
    Show site
    • Peking University First Hospital consecutively · Beijing, China
    Start date Nov 1, 2025→Sep 1, 2024 (now actual)
    Primary completion Dec 3, 2025→Aug 3, 2025 (now actual)
    Study completion Dec 3, 2025→Oct 3, 2025 (now actual)
    + 7 other changes: index terms, identifiers, verification date, oversight details, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06833658
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Sep 1, 2024
Primary completion
Aug 3, 2025
Completion
Oct 3, 2025
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion